Alzheimer's disease (AD) is characterized by multifactorial pathological processes, including cholinergic dysfunction and oxidative stress, highlighting the need for safer, multi-target interventions beyond current synthetic acetylcholinesterase (AChE) inhibitors. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.